This guidance has been updated and replaced by NICE technology appraisal guidance 939 ...

The expanded programme addresses longstanding inequalities in technology adoption across different NHS regions. Technologies meeting NICE's standards will receive strong recommendations for NHS-wide ...

NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this ...

Adults diagnosed with a functional neurological disorder are supported to manage symptoms that are a part of the disorder in non-specialist care. Adults with symptoms that occur as part of a ...

NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.

Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249] Medicine Not selected 15 September 2025 Modified release hydrocortisone capsules for treating adrenal insufficiency in ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.